Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Dow
Boehringer Ingelheim
Harvard Business School
Medtronic

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

Litigation Details for Kowa Company, Ltd. v. Aurobindo Pharma Limited (S.D.N.Y. 2014)

See Plans and Pricing

« Back to Dashboard

Kowa Company, Ltd. v. Aurobindo Pharma Limited (S.D.N.Y. 2014)

Docket   Start Trial Date Filed 2014-04-09
Court District Court, S.D. New York Date Terminated 2015-12-08
Cause 35:271 Patent Infringement Assigned To Paul Austin Crotty
Jury Demand Defendant Referred To
Parties AUROBINDO PHARMA LIMITED; AUROBINDO PHARMA USA INC.; CADILA HEALTHCARE LTD.; KOWA COMPANY, LTD.; KOWA PHARMACEUTICALS AMERICA, INC.; NISSAN CHEMICAL INDUSTRIES, LTD.; ZYDUS PHARMACEUTICALS (USA) INC.
Patents 5,753,675; 5,856,336; 6,465,477; 8,557,993
Attorneys Adam Phillip Samansky; Anthony Joseph Viola; Chandrika Vira; David Cotta; David G. Conlin; Deirdre M. Wells; Hemant Keeto Sabharwal; James Edward Nealon; Jennifer Lynn Dereka; Kathleen B. Carr; Paul Ainsworth; Peter John Cuomo; Sana Fatima Hussain; Steven Jerome Moore; Thomas Hoelder Wintner; Zachary Winthrop Silverman
Firms Edwards Wildman Palmer, LLP-MA; Mintz Levin Cohn Ferris Glovsky & Popeo, P.C.(NYC); Sterne Kessler Goldstein & Fox PLLC; Whiters Bergman LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Kowa Company, Ltd. v. Aurobindo Pharma Limited
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Kowa Company, Ltd. v. Aurobindo Pharma Limited (S.D.N.Y. 2014)

Date Filed Document No. Description Snippet Link To Document
2014-04-09 2 Cited U.S. PAIENT DOCUMENTS 5,753,675 -5l1998 Wauanasin ..... .... ....…1. This is an action for patent infringement arising under the patent laws of the United States… 13. United States Patent No. 5,856,336 ("the '336 patent"), entitled "Quinoline…assignment of the '336 patent, which expires on December 25,2020 pursuant to a patent-term extension. KCL…licensee for the '336 patent and KPA holds a license from KCL for the '336 patent. 15. External link to document
2015-11-04 93 infringing U.S. Patent Nos. 5,856,336 (“the ‘336 Patent”); 6,465,477 (“the ‘477 Patent”); and 8,557,993…the ‘993 Patent”). Defendants seek claim construction of the ‘336 Patent and the ‘477 Patent; Plaintiffs…Apotex”). 2 The ‘336 Patent is not at issue in the Apotex case. The ‘477 Patent is not at issue in the…Fed. Cir. 2008). II. The ‘336 Patent The ‘336 Patent consists of two claims. Claim 1 describes…construction is unnecessary. III. The ‘477 Patent The ‘477 Patent states that pitavastatin calcium (also External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Merck
Baxter
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.